In addition, I know that OCRM employee seems pleasant, but not that knowledgeable about their responsibilities. I have been as a research nurse, and then research coordinator in the past; I learned some thing about regulatory, communication and clinical practice. However, I do not really have any management experience in the pharmaceutical industry. Therefore, I need to update my knowledge of this market, create sensitive intuition and improve executive skills; my first step is market researchOver view of the market, this is a high cost and time consuming industry, the average cost to research and develop a new drug is estimated to be $2.6 billion (incorporated the cost of failures) and took 10~15 years for the new drug from investigational process to reach the market. (Pharmaceutical Research and Manufacturers of America, 2015). In addition, pharmaceutical industry is getting more competitive due to more merge companies and harder to get product approval by FDA. In addition, the number of new IND application is increasing in every fiscal year and FDA does not ease the regulatory or expedite the NDA review
In addition, I know that OCRM employee seems pleasant, but not that knowledgeable about their responsibilities. I have been as a research nurse, and then research coordinator in the past; I learned some thing about regulatory, communication and clinical practice. However, I do not really have any management experience in the pharmaceutical industry. Therefore, I need to update my knowledge of this market, create sensitive intuition and improve executive skills; my first step is market researchOver view of the market, this is a high cost and time consuming industry, the average cost to research and develop a new drug is estimated to be $2.6 billion (incorporated the cost of failures) and took 10~15 years for the new drug from investigational process to reach the market. (Pharmaceutical Research and Manufacturers of America, 2015). In addition, pharmaceutical industry is getting more competitive due to more merge companies and harder to get product approval by FDA. In addition, the number of new IND application is increasing in every fiscal year and FDA does not ease the regulatory or expedite the NDA review